Basit öğe kaydını göster

Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

dc.contributor.authorSevinc, Alper
dc.contributor.authorGuler, Nilufer
dc.contributor.authorOnur, Handan
dc.contributor.authorUslu, Ruchan
dc.contributor.authorAltinbas, Mustafa
dc.contributor.authorİÇLİ, FİKRİ
dc.contributor.authorAltundag, Kadri
dc.contributor.authorAKBULUT, HAKAN
dc.contributor.authorPAYDAŞ, SEMRA
dc.contributor.authorBasaran, Gul
dc.contributor.authorDogu, Gamze G.
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorGÖKMEN, ERHAN
dc.contributor.authorUYGUN, KAZIM
dc.contributor.authorUstuner, Zeki
dc.contributor.authorYAREN, ARZU
dc.contributor.authorDemirkan, Binnaz
dc.contributor.authorAta, Alper
dc.contributor.authorÖZKAN, METİN
dc.contributor.authorArican, Ali
dc.contributor.authorSaip, Pinar
dc.contributor.authorMandel, Nil M.
dc.contributor.authorErlap, Yesim
dc.contributor.authorCoskun, Ugur
dc.contributor.authorSezgin, Canfeza
dc.date.accessioned2021-03-05T10:21:18Z
dc.date.available2021-03-05T10:21:18Z
dc.date.issued2015
dc.identifier.citationİÇLİ F., Altundag K., AKBULUT H., PAYDAŞ S., Basaran G., Saip P., Dogu G. G. , Erlap Y., Uslu R., Sevinc A., et al., "Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)", BREAST CANCER, cilt.22, ss.480-485, 2015
dc.identifier.issn1340-6868
dc.identifier.othervv_1032021
dc.identifier.otherav_a2b35233-f7a1-478e-9c3a-a4025275ecc5
dc.identifier.urihttp://hdl.handle.net/20.500.12627/108915
dc.identifier.urihttps://doi.org/10.1007/s12282-013-0506-y
dc.description.abstractBackground Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey.
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectCerrahi Tıp Bilimleri
dc.subjectKadın Hastalıkları ve Doğum
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKADIN HASTALIKLARI & DOĞUM
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.subjectİç Hastalıkları
dc.titleNine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)
dc.typeMakale
dc.relation.journalBREAST CANCER
dc.contributor.departmentAnkara Üniversitesi , ,
dc.identifier.volume22
dc.identifier.issue5
dc.identifier.startpage480
dc.identifier.endpage485
dc.contributor.firstauthorID224590


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster